Trial · NCT00763256
The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics
NCT00763256, Phase 3, Completed, Colgate Palmolive; results first posted 2012-04-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics. Trials, record NCT00763256. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00763256
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics
- NCT number
- NCT00763256
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 33 participants, actual
- Lead sponsor
- Colgate Palmolive
- Conditions
- Periodontal Disease
- Interventions
- Triclosan, Fluoride, Fluoride
- First posted
- 2008-09-30
- Last updated
- 2015-07-28
- Results first posted
- 2012-04-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HbA1c Levels in Blood | 12 months | Glycated hemoglobin (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. In this study, blood is taken from each subject and HbA1c levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). |
| Primary | High Sensitivity CRP (C-Reactive Protein) | 12 months | CRP is a protein found in the blood and is a marker for inflammation in the body. Inflammation plays a role in the initiation and progression of cardiovascular disease. Blood is taken from each subject and CRP levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). |
| Primary | C-Peptide | 12 months | C-Peptide levels in blood indicate whether or not a person is producing insulin. This peptide is usually found in equal levels to insulin. C-peptide levels measured as a means of distinguishing type 1 diabetes and type 2 diabetes. Blood is taken from each subject and C-Peptide levels were measured at 12 months by Queensland Health Pathology Scientific Services (QHPSS). |
| Primary | Gingivitis Score (GI) | 12 months | Units on a scale 0 to 3 (0 = no inflammation, 1 = Mild inflammation-slight change in color and little change in texture 2 = Moderate inflammation-moderate glazing, redness, edema and hypertrophy. Tendency to bleed upon probing. 3 = Severe inflammation-marked redness and hypertrophy. Tendency to spontaneous bleeding) |
| Primary | P. Gingivalis | 12 months | Subgingival plaque samples were collected from all interproximal (mesial) sites and pooled prior to assessment. The samples will be analysed for the presence of P. gingivalis, using real time PCR to quantitate the numbers of bacteria. P. gingivalis is a non-motile, gram negative, anaerobic, pathogenic bacteria. It is linked to periodontal disease and causes collagen degradation. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | HbA1c Levels in Blood | 12 months | Percentage | MEAN | |
| PRIMARY | High Sensitivity CRP (C-Reactive Protein) | 12 months | mg/L | MEAN | |
| PRIMARY | C-Peptide | 12 months | nmol/L | MEAN | |
| PRIMARY | Gingivitis Score (GI) | 12 months | Units on a scale | MEAN | |
| PRIMARY | P. Gingivalis | 12 months | Pg/ng DNA | MEDIAN |
Source ClinicalTrials.gov
Results by group10
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| HbA1c Levels in Blood | Active Comparator | 9.47 | Standard Deviation 2.2 | Percentage | |
| HbA1c Levels in Blood | B - Placebo Comparator | 10.27 | Standard Deviation 2.4 | Percentage | |
| High Sensitivity CRP (C-Reactive Protein) | Active Comparator | 6.16 | Standard Deviation 5.5 | mg/L | |
| High Sensitivity CRP (C-Reactive Protein) | B - Placebo Comparator | 5.37 | Standard Deviation 3.8 | mg/L | |
| C-Peptide | Active Comparator | 1.20 | Standard Deviation 1.0 | nmol/L | |
| C-Peptide | B - Placebo Comparator | 1.04 | Standard Deviation 0.6 | nmol/L | |
| Gingivitis Score (GI) | Active Comparator | 0.89 | Standard Deviation 0.2 | Units on a scale | |
| Gingivitis Score (GI) | B - Placebo Comparator | 0.88 | Standard Deviation 0.1 | Units on a scale | |
| P. Gingivalis | Active Comparator | 209 | Inter-Quartile Range 0 to 23688 | Pg/ng DNA | |
| P. Gingivalis | B - Placebo Comparator | 22 | Inter-Quartile Range 0 to 15982 | Pg/ng DNA |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Active Comparator | 15 | |
| Overall Study | STARTED | B - Placebo Comparator | 18 | |
| Overall Study | COMPLETED | Active Comparator | 8 | |
| Overall Study | COMPLETED | B - Placebo Comparator | 8 | |
| Overall Study | NOT COMPLETED | Active Comparator | 7 | |
| Overall Study | NOT COMPLETED | B - Placebo Comparator | 10 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Active Comparator | ||
| Total, all-cause mortality | B - Placebo Comparator | ||
| Total, other adverse events | Active Comparator | 0 | 15 |
| Total, other adverse events | B - Placebo Comparator | 0 | 18 |
| Total, serious adverse events | Active Comparator | 0 | 15 |
| Total, serious adverse events | B - Placebo Comparator | 0 | 18 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Active Comparator vs B - Placebo Comparator: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00763256
GET https://conductscience.org/api/trials/v1/NCT00763256/registered